Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin/Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia. Frovocimab is used to study hypercholesterolemia.

Frovocimab is able to bind to the intact, untruncated PCSK9 protein. Its specific binding to intact PCSK9 is due to its binding epitope, specifically the linear sequence of amino acids 160-181 in the catalytic structural domain of human PCSK9, which is not present in the truncated form of PCSK9.
Frovocimab inhibits PCSK9 binding to LDLR while allowing normal protein hydrolytic cleavage to occur. After cleavage, inactive truncated PCSK9 is released from Frovocimab. [1]

Frovocimab, when administered intravenously at a dose of 10 mg/kg, significantly increased PCSK9 accumulation in mice expressing a non-cleavable human PCSK9 variant, resulting in a shorter duration of LDL lowering and accelerated clearance of LDL from the serum. [1]
Frovocimab was effective in lowering LDL cholesterol levels in monkeys when administered intravenously at a dose of 5 mg/kg and, unlike other PCSK9 monoclonal antibodies, it did not cause accumulation of intact PCSK9 in serum. [1]